
Adcendo
Developer of antibody-drug conjugates designed to create new medicines for cancer patients with significant unmet needs. The company's conjugates are directed at a target receptor, which is an approac...
Valuation
$209.9M
Latest known
Share Price
N/A
Total Raised
$240.9M
Last Round
N/A